Endurance Bio Overview

  • Year Founded
  • 2025

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Early Stage VC

  • Investors
  • 1

Endurance Bio General Information

Description

Developer of small molecule therapeutics designed to improve cellular function and treat metabolic and neurodegenerative diseases. The company offers orally bioavailable compounds, mitochondrial and lysosomal pathway activation, and regulation of cellular metabolism, enabling biopharmaceutical organizations to target disease mechanisms and support therapeutic development.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 10080 North Wolfe Road South West 3
  • Suite 300
  • Cupertino, CA 95014
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 10080 North Wolfe Road South West 3
  • Suite 300
  • Cupertino, CA 95014
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Endurance Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC 31-Dec-2025 Completed Clinical Trials - Phase 2
To view Endurance Bio’s complete valuation and funding history, request access »

Endurance Bio Patents

Endurance Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260199293-A1 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies Pending 02-Dec-2022
US-20250009714-A1 Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype Pending 02-Nov-2021
EP-4355326-A1 Therapeutically effective oral administration of a 2 arylbenzimidazole Pending 17-Jun-2021
EP-4355326-A4 Therapeutically effective oral administration of a 2 arylbenzimidazole Pending 17-Jun-2021
US-20240307356-A1 Therapeutically effective oral administration of a 2 arylbenzimidazole Inactive 17-Jun-2021 A61K31/4184
To view Endurance Bio’s complete patent history, request access »

Endurance Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Endurance Bio Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Remiges Ventures Venture Capital Minority
To view Endurance Bio’s complete investors history, request access »

Endurance Bio FAQs

  • When was Endurance Bio founded?

    Endurance Bio was founded in 2025.

  • Where is Endurance Bio headquartered?

    Endurance Bio is headquartered in Cupertino, CA.

  • What is the size of Endurance Bio?

    Endurance Bio has 5 total employees.

  • What industry is Endurance Bio in?

    Endurance Bio’s primary industry is Drug Discovery.

  • Is Endurance Bio a private or public company?

    Endurance Bio is a Private company.

  • What is Endurance Bio’s current revenue?

    The current revenue for Endurance Bio is .

  • Who are Endurance Bio’s investors?

    Remiges Ventures has invested in Endurance Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process